Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19.
The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV-2 IMMUNISATION)’ (Abstract no: OP137) was presented at UEG Week, October 8 – 11, 2022.
- What is known about the response to COVID-19 vaccinations in patients with inflammatory bowel disease (IBD)? (0:34)
- What were the eligibility criteria of your study? (2:29)
- What were the vaccine responses in patients with IBD and in those taking TNF antagonists? (3:15)
- On the basis of these findings, what are your recommendations for patients with IBD who are taking TNF antagonists?
Disclosures: Jayne Doherty has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!